efferalgan
upsa sas - paracetamolis - šnypščiosios tabletės - 500 mg; 80 mg; 150 mg; 30 mg/ml - paracetamol
efferalgan c
upsa sas - paracetamolis/askorbo rūgštis - šnypščiosios tabletės - 330 mg/200 mg - paracetamol, combinations excl. psycholeptics
ibustar
berlin-chemie ag (menarini group) - ibuprofenas - geriamoji suspensija - 20 mg/ml - ibuprofen
ibustar
berlin-chemie ag - ibuprofenas - geriamoji suspensija - 40 mg/ml - ibuprofen
dexmedetomidine accord
accord healthcare s.l.u. - dexmedetomidine - premedication - psicholeptikai - už sedacija suaugusiųjų icu (intensyvios slaugos skyrių) pacientams, kuriems reikalingas tam sedacija lygis ne giliau nei susijaudinimą, reaguodama į žodinis stimuliacija (atitinkamai į richmond, sujaudinimas-sedacija masto (rass) nuo 0 iki -3). už sedacija ne intubated suaugusiems pacientams prieš ir (arba) atliekant diagnostines ar chirurgines procedūras, reikalaujančias sedacija, i. procesinių/miega, sedacija.
azacitidine icg farma
icg farma, uab - azacitidinas - milteliai injekcinei suspensijai - 25 mg/ml - azacitidine
losartan potassium stada
stada arzneimittel ag - losartano kalio druska - plėvele dengtos tabletės - 100 mg - losartan
ibuprofen nvt
nvt, uab - ibuprofenas - minkštosios kapsulės - 400 mg - ibuprofen
kalydeco
vertex pharmaceuticals (ireland) limited - ivakaftoras - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.